225AcPSMAI&T: Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy
Study Details
Study Description
Brief Summary
225Ac-PSMA I&T is a radiopharmaceutical for therapy of prostate cancer. PSMA is overexpressed on prostate cancer cells. Actium-225 is an alpha emitting radionuclide. When PSMA I&T is labelled with Actium-225, it can be applied as therapy for prostate cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Rationale:
225Ac-PSMA I&T is a radiopharmaceutical for therapy of prostate cancer. PSMA is overexpressed on prostate cancer cells. Actium-225 is an alpha emitting radionuclide. When PSMA I&T is labelled with Actium-225, it can be applied as therapy for prostate cancer.
Objective:
To evaluate the tolerability and safety of 225Ac-PSMA I&T in patients with metastatic prostate cancer and recommend a dose for further phase 2 studies.
Study design:
A clinical prospective, single-center, single-arm, phase I dose escalation therapy study.
Study population:
Up to 30 patients with advanced metastatic castration-resistant prostate cancer (mCRPC).
Intervention:
Patients with advanced mCRPC will receive therapy with 225Ac-PSMA I&T. The first dose-level will not exceed 8 megabecquerel (MBq), as this is reported in the literature as a save activity for treatment. A Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) with Gallium-68-PSMA I&T (68Ga) will be performed to calculate the precise dose-level needed and as a verification the precise dose-level will be compared with the dose-level of 8 MBq. In the first week after therapy, the PET-MRI will be repeated to observe any effects of the alpha radiation on the metastases and observe the potential changes in 68Ga-PSMA I&T uptake. Eight weeks after the first cycle, patients will receive the second cycle of 225Ac-PSMA I&T. If no Dose Limiting Toxicity (DLT) occurs, the dose can be increased for the next DL. If a DLT occurs, the cohort will be expanded to 6 patients. After establishing the recommended dose, an expansion cohort will be opened with a total of 12 patients.
Main study endpoints:
To investigate the safety, tolerability and biochemical effects of 225Ac-PSMA I&T injected in patients with metastatic prostate cancer.
Primary objective:
- To assess the safety and tolerability of 225Ac-PSMA I&T administered intravenously
Secondary objectives:
-
To predict and calculate the absorbed-dose in critical organs (e.g. salivary glands, kidneys, bone marrow) by 68Ga-PSMA I&T PET-MRI
-
To evaluate the effects of the radionuclide therapy on metastases in the days after therapy using 68Ga-PSMA I&T PET-MRI
-
To evaluate the biochemical effects of 225Ac-PSMA I&T therapy in patients with metastatic prostate cancer
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 225Ac-PSMA I&T 225Ac-PSMA I&T |
Radiation: Radionuclide Therapy
To evaluate the tolerability and safety of 225Ac-PSMA I&T in patients with metastatic prostate cancer
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence and severity of Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0 [4 years]
Safety and tolerability assessment
- Absolute values and changes from baseline in laboratory parameters (hematology, blood chemistry and urinalysis), including assessment of shifts from baseline to abnormal values on treatment [4 years]
Safety and tolerability assessment
- Absolute values and changes from baseline in vital signs & ECG parameters [4 years]
Safety and tolerability assessment
Secondary Outcome Measures
- To predict and calculate the absorbed-dose in critical organs (e.g. salivary glands, kidneys, bone marrow) by 68Ga-PSMA I&T PET-MRI [4 years]
Dosimetry
- Changes in SUVmax of the target lesions on PET-MRI and morphological changes evaluated on MRI [4 years]
Direct effect of 225Ac-PSMA I&T
- Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria v.1.1. [4 years]
Preliminary efficacy
- Percent changes from baseline in tumor size where tumor size is defined as the sum of all target lesions as measured by RECIST criteria v.1.1. [4 years]
Preliminary efficacy
- Prostate Specific Antigen(PSA) response rate assessed from treatment visit 1 defined as a decrease in PSA of ≥ 50% from baseline. [4 years]
Preliminary efficacy
- Percent change from baseline in PSA as a continuous endpoint by visit and maximum reduction during the study [4 years]
Preliminary efficacy
- Percent change from baseline values of pain questionnaire at every treatment visit [4 years]
Preliminary efficacy
- Overall Survival (OS) defined as the time from the date of first dose of 225Ac-PSMA I&T treatment to the date of death due to any cause. [4 years]
Preliminary efficacy
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histopathological proven metastatic castration resistant prostate cancer. Castrationresistant disease is defined as a serum testosterone level of 50 nanogram per deciliter or lower (≤1.7 nanomol per liter) after bilateral orchiectomy or during maintenance treatment consisting of androgen-ablation therapy with a luteinizing hormone-releasing hormone agonist.
-
Evidence of progressive disease, defined as 1 or more Prostate Cancer Work Grouping 3 (PCWG3) criteria: - PSA level ≥ 1 ng/mL that has increased on at least 2 successive occasions at least 1 week apart
-
Progression as defined by RECIST 1.1 with PCGW3 modifications
-
Progression after at least one line of chemotherapy and/or one line of nonsteroidal antiandrogen (NSAA).
-
No active anti-tumor therapy, except for androgen deprivation therapy in combination with at least one androgen receptor-targeted agent
-
Willing and able to undergo 2 cycles of 225Ac-PSMA I&T therapy and 3 PET-MRI scans in 16 weeks and comply with protocol
-
Signed and dated written informed consent by the patient (or legal representative) prior to any study-specific procedures.
-
Age ≥ 18 years.
-
Eastern Cooperative Oncology Group (ECOG) performance-status score 0-2.
-
Use of highly effective methods of contraception (female partners of male participants)
-
During the trial and 6 months after completion of the study or willing to practice sexual abstinence.
Exclusion Criteria:
-
Concurrent severe illness or clinically relevant trauma within 2 weeks before the administration of the investigational product that might preclude study completion or interfere with study results
-
Serum hemoglobin ≤ 6.2 mmol/L, total white blood cell (WBC) count ≤ 3.5·109/L, absolute neutrophil count ≤ 1.5·109/L, platelet count ≤ 100·109/L, serum creatinine concentration ≥ 150 umol/L (≥ 1.7 mg/dL), serum albumin <30 g/L, bilirubin ≥ 1.5 x upper limit normal (ULN), aspartate transaminase (ASAT) ≥ 3 x ULN and alanine aminotransferase (ALAT) ≥ 3 x ULN (or bilirubin ≥ 3 x ULN, ASAT ≥ 5 x ULN and ALAT ≥ 5 x ULN in the case of pre-existing liver metastases at baseline)
-
Concurrent bladder outflow obstruction or unmanageable urinary incontinence
-
Known or expected hypersensitivity to Gallium-68, Actinium-225, PSMA I&T, or any excipient present in 225Ac/68Ga-PSMA I&T
-
Prior administration of a radiopharmaceutical within a period corresponding to 8 halflives of the radionuclide used on such radiopharmaceutical
-
Prior treatment with any radionuclide therapy
-
History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
-
Central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression
-
Radiation therapy within 4 weeks of first dose (or local or focal radiotherapy within 2 weeks of first dose)
-
Male subjects unwilling to abstain from donating sperm during treatment and for an additional 6 months after the last dose
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Erasmus Medical Center | Rotterdam | Zuid-Holland | Netherlands | 3015GD |
Sponsors and Collaborators
- Erasmus Medical Center
- Dutch Cancer Society
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NL73234.078.20